Treatment approach for CALGB 10403/ECOG C10403/SWOG C10403, an intergroup phase 2 clinical trial for adolescents and young adults with untreated acute lymphoblastic leukemia
| Component . | Duration . | Agents and days administered . |
|---|---|---|
| Remission induction (extended remission induction also given to some patients, depending on D29 BMBx) | 4 wk | Intrathecal Ara-C (D1) |
| Intrathecal MTX (D8, 29) | ||
| Prednisone (D1-28) | ||
| Vincristine (D1,8,15,22) | ||
| Daunorubicin (D1,8,15,22) | ||
| Peg-asparaginase (D4) | ||
| Remission consolidation | 8 wk | Intrathecal MTX (D1,8,15,22) |
| Cyclophosphamide (D1,29) | ||
| Ara-C (D1-4,8-11,29-32,36-39) | ||
| 6-MP (D1-14, 29-42) | ||
| Vincristine (D15,22,43,50) | ||
| Peg-asparaginase (D15,43) | ||
| Interim maintenance | 8 wk | Intrathecal MTX (D1,31) |
| Vincristine (D1,11,21,31,41) | ||
| Methotrexate (D1,11,21,31,41) | ||
| PEG-asparaginase (D2,22) | ||
| Delayed intensification | 8 wk | Intrathecal MTX (D1,29,36) |
| Dexamethasone (D1-7,15-21) | ||
| Doxorubicin (D1,8,15) | ||
| Peg-asparaginase (D4,43) | ||
| Cyclophosphamide (D29) | ||
| Ara-C (D29-32,36-39) | ||
| 6-TG (D29-42) | ||
| Maintenance | Repeated 12-wk courses | Intrathecal MTX (D15, and D29 of first 4 courses of maintenance) |
| Total duration of maintenance: | Vincristine (D1,29,57) | |
| 2 y from IM for females | Dexamethasone (D1-5,29-33, 57-61) | |
| 3 y from IM for males | 6-MP (D1-84) | |
| Methotrexate (D8,15,22,29,36,43,50,57,64,71,78; held on D29 of first 4 courses of maintenance when IT is given) |
| Component . | Duration . | Agents and days administered . |
|---|---|---|
| Remission induction (extended remission induction also given to some patients, depending on D29 BMBx) | 4 wk | Intrathecal Ara-C (D1) |
| Intrathecal MTX (D8, 29) | ||
| Prednisone (D1-28) | ||
| Vincristine (D1,8,15,22) | ||
| Daunorubicin (D1,8,15,22) | ||
| Peg-asparaginase (D4) | ||
| Remission consolidation | 8 wk | Intrathecal MTX (D1,8,15,22) |
| Cyclophosphamide (D1,29) | ||
| Ara-C (D1-4,8-11,29-32,36-39) | ||
| 6-MP (D1-14, 29-42) | ||
| Vincristine (D15,22,43,50) | ||
| Peg-asparaginase (D15,43) | ||
| Interim maintenance | 8 wk | Intrathecal MTX (D1,31) |
| Vincristine (D1,11,21,31,41) | ||
| Methotrexate (D1,11,21,31,41) | ||
| PEG-asparaginase (D2,22) | ||
| Delayed intensification | 8 wk | Intrathecal MTX (D1,29,36) |
| Dexamethasone (D1-7,15-21) | ||
| Doxorubicin (D1,8,15) | ||
| Peg-asparaginase (D4,43) | ||
| Cyclophosphamide (D29) | ||
| Ara-C (D29-32,36-39) | ||
| 6-TG (D29-42) | ||
| Maintenance | Repeated 12-wk courses | Intrathecal MTX (D15, and D29 of first 4 courses of maintenance) |
| Total duration of maintenance: | Vincristine (D1,29,57) | |
| 2 y from IM for females | Dexamethasone (D1-5,29-33, 57-61) | |
| 3 y from IM for males | 6-MP (D1-84) | |
| Methotrexate (D8,15,22,29,36,43,50,57,64,71,78; held on D29 of first 4 courses of maintenance when IT is given) |
D indicates day; BMBx, bone marrow biopsy; IM, induction maintenance; and IT, interathecal.